The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT
Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
Quality of Life Disparities Persist in R/R Multiple Myeloma Despite Universal Health Care: Francesco Sparano, MSc
Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS
The Role of MRD Status in Post-ASCT Treatment Decisions and Clinical Integration
Evaluating First-Line Treatment Options: Quadruplet vs Triplet Regimens and NCCN Guidelines
CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS
DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA
Treatment Approaches and Goals: Transplant-Eligible vs. Transplant-Ineligible Patients
The Role of ASCT in Frontline Myeloma: Comparative Risks and Benefits with Other Standard Treatment Approaches
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Closing Gaps in CLL Care: Managed Care Insights and Strategies
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens
Streamlining Transitions Between Academic and Community Centers
Proactive CRS Management: The Role of Tocilizumab and Beyond